NEW YORK (GenomeWeb) – Life sciences informatics company Benchling said today that it has closed a $14.5 million Series B round of venture capital. Benchmark led the round, with participation from Fidelity Investments' F-Prime Capital and previous investor Thrive Capital.

As as result of the investment, Benchmark General Partner Eric Vishria is joining the board of San Francisco-based Benchling. He touted the rise of biologics as a major factor in backing Benchling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.